The 68 Ga-labeled iron oxide (Fe 3 O 4 ) nanocomposites ( 68 Ga(NF)HFCNP) have been fabricated for positron emission tomography (PET)/magnetic resonance imaging (MRI) diagnosis and targeted cancer therapy. These radioisotopes labeled nanocomposites with folate conjugation have improved the targeting property toward cancer cells. The chemotherapeutic drug doxorubicin (DOX) was loaded with 68 Ga-labeled Fe 3 O 4 nanoparticles ( 68 Ga(NF)HFCNP) via intermediate DOX-Fe 2+ complex. The average loading efficiency of DOX was 35% for NFHFCNP and 41% for HFCNP, respectively. In drug release profile, the release rate of DOX from the nanocomposite was increased with respect to time. The cell lines, KB and A549 treated with 68 Ga(NF)HFCNP showed high cell viability and excellent cell uptake. Meanwhile, the DOXloaded nanocomposites exhibit high cytotoxicity toward these cell lines. These properties make 68 Ga(NF)HFCNP nanocomposite as a potential dual theragnostic probe for PET/MRI and targeted chemotherapy for cancer cells.
Introduction
Cancer is a disease which can break orderly process of normal cells in the body and causes death. Despite the technical advancement of cancer diagnosis and therapy for last few decades, it has remained as a major public health concern. There are conventional treatments for cancer such as surgery, radiation, hormone, and chemotherapy. Among these, the most common therapeutic approach is chemotherapy which has been used either alone or in combination with other therapeutic techniques. [1] [2] [3] Chemotherapy uses a highly efficient antineoplastic agent that kills cancer cells by preventing cell division or by drug toxicity which includes the anthracycline antibiotics; adriamycin and doxorubicin (DOX). DOX has been proven to be a very effective drug for the treatment of various cancers. 4 Nevertheless, the severe side effects such as drug resistance and non-selective cytotoxicity curtail the utility of this drug. Therefore, it is necessary to develop site-specific delivery system to transfer drug and it can nullify the major obstacles of toxicity and drug resistance. [2] [3] [4] Generally, nanoscale anticancer drug carriers have favorable properties like enhanced permeability and retention (EPR) effect. The highly stable nano-based carrier avoids the rapid renal excretion and prevents recognition by the reticuloendothelial system (RES), which enable effective accumulation in a solid tumor. As a result, those properties can decrease severe side effects of the drug by minimizing non-specific interactions. 3, 5, 6 Recently, anticancer drug carriers based on magnetic nanoparticles (NPs) are effective and attractive approach for the biomedical applications. Superparamagnetic iron oxide (Fe 3 O 4 ) NPs are benefited as probe and delivery system for biological diagnosis and therapy because of their excellent chemical stability and biocompatibility. [7] [8] [9] [10] [11] Specifically, radioisotope-labeled magnetic NPs are ideal probe for positron emission tomography (PET)/magnetic resonance imaging (MRI) which is a powerful tool to obtain necessary information in biomedicine. 7, 8, 12 In the beginning, 11 C (t 1/2 = 20 min), 13 N (t 1/2 = 10 min), 15 O (t 1/2 = 2 min), and 18 F (t 1/2 = 110 min) were the most used organic radionuclides for PET analysis. However, they have some limitations including high production cost for using cyclotron and relatively short half-lives. One of the alternative approach is to use metal radionuclide including 68 Ga (t 1/2 = 68 min, β + = 89% and electron capture (EC) = 11%), which can be obtained easily from 68 Ge/ 68 Ga generator without the serve of cyclotron. 8 [20] [21] [22] .
Preparation of HFCNP and NFHFCNP.
68 Ga-labeled NPs were synthesized according to the scheme shown in Figure S1 , Supporting Information. In the first step, the citrate was attached on the surface of iron oxide (FCNP) based on the protocol reported by Nigam et al. and Bumb et al. 8, 10, 23 The synthesized FCNP NPs (JCPDS Card No. 19-0629, a = 8.396 Å) have a negative surface charge because of the presence of carboxylate group and the average particle size was~9 nm ( Figure S2) . 8 From the prepared FCNP (4 mg/mL) solution, 5 mL were stirred with 100 μL of iodomethane at 40 C for 12 h and washed with methanol (12 000 rpm, 10 min). Then, 100 μL of hydrazine were added to the mixture and refluxed at 40 C for 5 h and stirred overnight at room temperature (RT). The obtained mixture (HFCNP) was washed with ethanol. NFHFCNP was prepared by reacting 10 mL of HFCNP (0.2 mg/mL) with 5 mg of (ρ-SCN-Bn)-NOTA and 8 mg of folate at RT for 20 h in the presence of triethylamine, which acts as base. Finally, the resulting mixture (NFHFCNP) was washed and dispersed in ethanol solution. 8 The structure of synthesized HFCNP and NFHFCP are shown in Figure 1 . The NFHFCNP has folate and NOTA as a chelate agent on the surface and the HFCNP has hydrazide with citrate group on the surface. The functional groups on HFCNP have many oxygen and amine groups as hard Lewis base. In addition, HFCNP can have dual functions as chelate agent and diagnosis probe. Ga can be classified as a Lewis acid and form stable coordinated complexes with oxygen, nitrogen, and sulfur donor atom. 24, 25 From the above-mentioned properties, it is clear that the Ga can easily bind to HFCNP without any chelating agent as well as NFHFCNP. Radioisotope 68 Ga Labeling with HFCNP and NFHFCNP. The non-radioactive reference compounds, GaHFCNP and GaNFHFCNP were prepared by reacting NPs with GaCl 3 stock solution (1:10 molar equiv). The mixture of NPs (0.1 mg/mL, 6 mL) and GaCl 3 stock solution (500 μL) was stirred for 10 min at 100 C under refluxing condition. After 10 min, the mixture was thoroughly washed and dispersed in deionized water (DW GaNFHFCNP were measured using ITLC-SG eluted with 0.1 M citric acid as a mobile phase. 8, 26 The AR-2000 radio-TLC Imaging Scanner and CRC dosemeter were used to measure the radioactivity. In Vitro Stability of 68 Ga Labeling of HFCNP and NFHFCNP in Human Serum.
68 Ga-labeled HFCNP (200 μL) and NFHFCNP (200 μL) were incubated with 1 mL of human serum at 37 C under 5% CO 2 for 15, 30, 60, 90, and 120 min to evaluate the in vitro stability. After each time intervals, the stability was monitored through ITLC-SG using 0.1 M citric acid. 19, 20 Release Profile of Doxorubicin-loaded HFCNP and NFHFCNP. The drug loading efficiency and releasing profile of DOX-(NF)HFCNP was recorded using fluorescence spectrometer. DOX-loaded (NF)HFCNP was prepared according to the method proposed by Munnier et al. 27 The drug binding on NPs surface was investigated through a preformed DOX-Fe 2+ complex, which is a mixture of DOX (300 μg/mL in pH 7.4 PBS) and (NH 4 ) 2 Fe(SO 4 ) 2 Á6H 2 O (450 μg/mL in DW). Then, the DOX-Fe 2+ complex was incubated with (NF)HFCNP under dark for 15 min. Various mass ratios of DOX 0.20/0.40/0.83/0.96 (w/w) with (NF) HFCNP (120 μg/mL) were prepared. After incubation, the DOX-(NF)HFCNP was centrifuged (15 000 rpm, 10 min, 4 C) to eliminate the non-conjugated DOX-Fe 2+ complex in supernatant. The DOX-loaded (NF)HFCNP was dispersed in sodium buffer solution (pH 4) for 20 min at 37 C in shaking incubator to measure the DOX loading efficiency. 27 The sample was centrifuged and the released DOX concentration in supernatant was measured utilizing fluorescence spectrometry (Perkin Elmer LS 55B Luminescence Spectrometer, Perkin Elmer, Seoul, Korea). The in vitro release of DOX from (NF)HFCNP was studied in PBS (pH 7.4) at 37 C. To measure the drug releasing rate, 200 μL of DOX-loaded (NF)HFCNP [DOX/(NF)HFCNP-0.40 (w/w), 120 μg/mL] was added to 3.8 mL of PBS (pH 7.4) and incubated at 37 C under constant shaking. 27 After subsequent time intervals, the tube was centrifuged (15 000 rpm for 10 min, 4 C) and the DOX released in supernatant from (NF)HFCNP was determined by fluorescence spectrometry at 556 nm (excitation wavelength 490 nm, emission range 530-700 nm). Each experiment was carried out in triplicate. Cellular Uptake. Cell uptake studies were performed for KB and A 549 cell lines by the fluorescence microscopy (EVOS FL Auto, Life Technologies). Initially, the fluorescein isothiocyanate (FITC)-conjugated (NF)HFCNP was prepared by mixing (NF)HFCNP solution (120 μg/mL, 1 mL) in ethanol and FITC solution (1 mg/mL, 0.5 mL) in acetone/water medium (0.3/2.7). As prepared solution was incubated for 20 h at 37 C in shaking incubator under dark condition. 28 Then, the obtained mixture was thoroughly washed with PBS (pH 7.4) to eliminate the unreacted FITC and dispersed in 1 mL of cell culture medium (RPMI 1640). Cancer cells were placed in 8-well microscopy chamber with 1.0 × 10 4 cells per well and allowed to grow for 24 h. After incubation, the cells were washed with PBS and fixed with 4% paraformaldehyde (200 μL) for 15 min, Then, the cells were again washed and incubated with FITC-conjugated (NF)HFCNP (200 μL) for 30 min. After the whole incubation process, the non-uptake (NF)HFCNP was washed with PBS and the nuclei of cell was stained with 200 μL of 4 0 ,6-diamidino-2-phenylindole (2 μg/mL) in water for 10 min under dark. 29 In addition, to compare GaNHFCNP (5 μCi/well) at 40 C for 0.5 and 1 h. Then, surface-bound radioactivity materials were removed using PBS and the cells were suspended in 0.1% sodium dodecyl sulfate in PBS. The radioactivity of cells and supernatant was measured by utilizing a gamma counter. C. The cell viability was calculated by recording absorbance at 450 nm. 8, 10 %Viability = absorbance of sample=absorbance of control ð Þ ×100 resultant figure, the samples FHFCNP and NFHFCNP show absorption peaks at 280 and 360 nm confirming the covalent attachment of the folate with NPs. 15 But the corresponding folate absorption peaks were not observed in HFCNP and NHFCNP samples. Thus, the composite NFHFCNP with folate can easily be attached on tumor cell for targeted therapeutic. 30 After chelating reaction for 10 min, the compound with radioactivity of 277 μCi of 68 GaNFHFCNP and 280 μCi of GaHFCNP, which depicts that the 68 Ga atom was situated in the center of 68 GaHFCNP composites, which was further encapsulated by amine donors and conjugate with citrate group. 24, 25 The in vitro stability of 68 GaNFHFCNP and 68 GaHFCNP composites are shown in Figure S3 . The resultant plot displays that the HFCNP can strongly bind with 68 Ga compared with NFHFCNP, because 68 GaHFCNP exhibited higher stability of~97.5% than 68 GaNFHFCNP of~87.5% at 120 min. From these results, the encapsulation of Ga in HFCNP shows more strong binding effect than chelation effect of NOTA. 24, 25 Cell uptake of Ga(NF)HFCNP on KB and A 549 cell lines are shown in Figure S4 Figure 3 .
Results and Discussion
In our previous research, we expected that the SK-BR-3 (FR-) cell membrane have more negatively charged sites than that of CT-26 (FR+) for high NPs adsorption. But the 68 GaNHFCNP composite showed comparatively high uptake to SK-BR-3 (FR-) than that of CT-26 (FR+) cell line. 8 To enhance the uptake of the NPs on CT-26 (FR+) Drug loading efficiency and releasing profile of DOX from NPs were estimated using fluorescence spectroscopy. After the formation of intermediate DOX-Fe 2+ complex, the color of sample changes from bright red (DOX) to dark red (DOX-Fe 2+ ) as represented in Figure S5 . The loading efficiency of different concentration of DOX on (NF) HFCNP was calculated using the following relation and the resultant calibration curve of DOX solution is shown in Figure S5 . 27 Loading efficiency % ð Þ = D2=D1 × 100 concentration of DOX used before reaction (D1) and after reaction (D2). The DOX can bind to NPs by means of ionic interaction and iron chelation of DOX-Fe 2+ . The Fe 2+ ion has a role to form an intermediate between DOX and NPs. Both HFCNP and NFHFCNP have many oxygen and nitrogen groups, which can easily chelate with iron ion (Figure 1) . 27 At pH 6, the DOX is positively charged by protonated primary amine. 10 The surface charge of synthesized HFCNP was observed to positive charge (+8.84 mV) 8 and that of NFHFCNP shows negative charge (−14.85 mV). Thus, the DOX has more affinity to bound with negatively charged NFHFCNP than HFCNP. Figure 4(a) shows the loading efficiency with respect to various weight ratios of DOX in HFCNP and NFHFCNP nanocomposites. From the resultant plot, the loading efficiency of DOX on HFCNP is higher than that of NFHFCNP. Moreover, the compounds exhibit nearly similar value for various mass ratios of DOX/NPs (0.2/0.4/0.83/0.96). These observations show that the binding of DOX to HFCNP is mainly afforded by iron chelation. Moreover, both the compounds possess almost constant DOX loading efficiency from 31.32 AE 0.19% to 38.28 AE 0.18% for NFHFCNP and 40.74 AE 0.02% to 43.87 AE 0.01% for HFCNP. The resultant drug releasing profile of NPs are shown in Figure 4 (b). The release rate of DOX from both the nanocomposite, HFCNP and NFHFCNP, depend up on time. The DOX release from NFHFCNP was increased sharply up to 8 h (47 AE 0.004%) and then, the releasing rate was gradually slowed and about 67 AE 0.002% released after 48 h. 27 The release of DOX from NFHFCNP could be attributed to the weakening of the electrostatic interaction between DOX and NPs. 10, 27 In case of HFCNP, the DOX was very slowly released about 19.6 AE 0.32% and 40.9 AE 1.4% after 24 and 48 h by hydrolysis. 27 The HFCNP and NFHFCNP showed a different releasing profiles of drug in spite of the same base NPs. This experiment evidence that the drug releasing profile can be adjusted by modifying the surface state of NPs. Figure 5 (a) shows the cell viability of KB and A549 incubated with Ga(NF)HFCNP for 48 and 72 h. After the incubation period, KB and A549 cell lines exhibited higher viability almost 100% toward Ga(NF)HFCNP. The small variation of cell viability above 100% may be because of the properties of iron oxide, which can sometimes facilitate the cell growth. 10 Moreover, the cells can continuously grow even at high concentration of Ga(NF)HFCNP. This result represents the nontoxicity and excellent biocompatibility of Ga(NF)HFCNP. However, DOX-loaded NFHFCNP shows high cytotoxicity toward all tested cells, where each cell was affected by DOX-loaded NFHFCNP with different force. Even though the low concentration of DOX can also kills enough cancer cells. The cytotoxicity of DOX-loaded NFHFCNP for 24 and 48 h was shown in Figure 5 (b). In case of HFCNP, KB and A 549 cell lines can survived >80% even at strong concentration because of its slow drug releasing profile. Even after 48 h incubation, GaHFCNP shows cytotoxicity on the tested cells but the effects is comparatively less than that of GaNFHFCNP. These difference in cytotoxicity level is mainly because of the release rate of NFHFCNP and HFCNP, which was approximately 67 and 40%, respectively. The exact statistical values of cell viability and cytotoxicity are shown in Tables S6 and S7 .
Conclusion
In conclusion, we described the synthesis and evaluation of 2+ complex have a high cytotoxicity on the tested cells. The DOX loading efficiency shows nearly similar value for various mass ratio of DOX/NPs. The HFCNP showed higher loading efficiency than NFHFCNP and it released about 61 AE 0.001% and 67 AE 0.002% of loaded DOX after 24 and 48 h, respectively. But HFCNP shows very slow drug releasing rate of 19.6 AE 0.32% for 24 h and 40.9 AE 1.4% for 48 h. These detailed studies establish that 68 GaHFCNP and GaNFHFCNP exhibit promising application for cancer contrast of PET/MRI and developing drug delivery for targeted chemotherapy.
